Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration
Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, announced that it has entered into a definitive agreement for a $430 million financing collaboration with funds managed by Blackstone (NYSE: BX). As part of the collaboration, Blackstone Life Sciences and Blackstone Credit have agreed to provide Amicus with a $400 million senior secured term loan facilitating a refinancin...
Brad Colman Simon Harford Bradley Campbell Blackstone Life Sciences Amicus Therapeutics Blackstone Enter
Source: webwire.com